Aim Many randomized controlled trials (RCTs) have investigated the use of interleukin 6
antagonists for the treatment of coronavirus disease 2019 (COVID‐19), yielding inconsistent …

Introduction Since the beginning of the COVID-19 pandemic, the repurposing of medicines
has been pursued to find interventions effective in preventing fatal outcome of the disease …

The study aimed to evaluate severe COVID-19 treatment approaches. We conducted a meta-
analysis of randomized controlled trials (RTCs) with standard of care (SoC) as a control …

Hyperinflammation in COVID-19 plays a crucial role in pathogenesis and severity; thus,
many immunomodulatory agents are applied in its treatment. We aimed to identify good …

Background Studies of inpatient coronavirus disease 2019 (COVID-19) mortality risk factors
have mainly used data from academic medical centers or large multihospital databases and …

Abstract 'Long COVID'affects nearly one in five adults who have had coronavirus disease
2019 (COVID-19), yet the mechanisms underlying this disorder remain poorly understood. In …

BACKGROUND Severe acute respiratory syndrome coronavirus 2 is the virus that causes
coronavirus disease 2019. Over six million deaths worldwide have been associated with …

SALAZAR, Martín et al. Utilización precoz de tocilizumab en pacientes internados con
COVID-19 grave y crítica: un estudio multicéntrico en la Provincia de Buenos Aires …

Autoimmune disorders of the central nervous system following COVID-19 infection include
multiple sclerosis (MS), neuromyelitis optica spectrum disorder, myelin oligodendrocyte …

The COVID-19 pandemic and the strain it placed on healthcare systems highlighted a key
role for real-world data in quickly generating health evidence. A growing demand for large …